Annual Report 2003 Aventis - Sanofi

Therapeutic Area Key Developments
RESPIRATORY/ALLERGIES
ANTI-INFECTIVES
ARTHRITIS/OSTEOPOROSIS
CENTRAL NERVOUS SYSTEM
(5)
(3)
(6)
· Telfast 30 mg tablets receive EU approval for pediatric use (6-11 years)
· A New Drug Application for Allegra-D 24 hour tablet is submitted to
the FDA in December
· Patient preference study confirms that Nasacort AQ is preferred by
patients 2 to 1 over competing products based on sensory attributes
· Nasacort aerosol nasal inhaler removed from the market in July 2003
in compliance with the Montreal Protocol
· Approved and launched in Canada, Japan and Turkey
· Achieves status as best antibiotic launch in France, Mexico,
Belgium, Greece, Turkey and Finland
· Submitted in the UK (EU-RMS) (4) for the treatment of prostatitis
· Approved in the UK (EU-RMS) for the treatment of uncomplicated
urinary tract infections
· Approved for pediatric use in Japan
· Leading antibiotic for the treatment of serious Gram-positive
infections in Japan and the UK
· New 35 mg once-weekly formulation successfully launched in
major European and International markets
· Differentiation achieved by establishing bone quality as a key
measure of bone health
· Receives FDA approval for additional indication to improve physical
function in rheumatoid arthritis
· Approved and launched in Japan
· Launched in French pharmacies in September 2003
· Continued excellent market penetration in Europe
· Fastest-growing multiple sclerosis therapy worldwide
Important notice: The therapeutic indications mentioned in this document do
not necessarily correspond to the exact indications registered in every country
where the relevant pharmaceutical products are marketed and sold. The
products identified in this document are only a selection of the total product
offering of Aventis.
2003 Key Figures
Sales (in e million) Activity Variance*
1 736 1.1 %
278 -0.7 %
115 135 %
216 -12.3 %
207 -1.1 %
194 81.4 %
255 8.3 %
617 27.3 %
(1) Licensed from Yakult Honsha (not sold by Aventis in the United States)
(2) Includes sales by the joint venture Aventis Pasteur MSD, which is accounted for
using the equity method
(3) Licensed from Daiichi (not sold by Aventis in the United States)
(4) EU-RMS = European Union Reference Member State
(5) Sold in cooperation with Procter & Gamble Pharmaceuticals; sales consolidated by Aventis
(6) Sold in cooperation with Teva Pharmaceutical Industries